Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.

By Jayaprakash K Nair, J. Willoughby, Amy Chan, K. Charissé, Md. Rowshon Alam, Qianfan Wang, M. Hoekstra, P. Kandasamy, A. Kel'in, S. Milstein and 15 more. Journal of the American Chemical Society, 2014

1,018 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1fd4a473a0cacd40ea2debcba5fd8b5472ce1b2a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Juliano

In Molecular Biology

1. Aaron D Springer
2. S. Dowdy
3. R. Juliano

Citations in the corpus

• The delivery of therapeutic oligonucleotides (2016, background): “Thus, the ASGR has many desirable aspects for targeted delivery of oligonucleotides including cell-type selectivity, high expression levels, rapid internalization and recycling, and the existence of well-characterized small ligands.”
• GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics (2018, background): “The prototypical siRNA conjugate is a trimer of Nacetylgalactosamine (GalNAc), which avidly binds to the Asialoglycoprotein receptor (ASGPR) that is predominantly expressed on liver hepatocytes [7,8].”